1446411-32-0 Usage
General Description
α-(2-azidoethyl)-ω-(carboxymethoxy)hexa(oxyethylene) is a chemical compound with the molecular formula C16H30N4O9. It is a polymeric compound formed by ethylene oxide units linked together with azide and carboxymethoxy groups at each end. α-(2-azidoethyl)-ω-(carboxymethoxy)hexa(oxyethylene) is commonly used in the field of organic chemistry as a reactant for the synthesis of various polymers and materials. Its unique structure allows for multiple functional groups to be attached, making it suitable for a wide range of applications such as drug delivery systems, surface coatings, and biomaterials. Additionally, the presence of azide groups in the molecule enables click chemistry reactions, making it a versatile building block in molecular design and organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 1446411-32-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,6,4,1 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1446411-32:
(9*1)+(8*4)+(7*4)+(6*6)+(5*4)+(4*1)+(3*1)+(2*3)+(1*2)=140
140 % 10 = 0
So 1446411-32-0 is a valid CAS Registry Number.
1446411-32-0Relevant articles and documents
Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction
Béquignat, Jean-Baptiste,Boucheix, Claude,Canitrot, Damien,Chezal, Jean-Michel,Degoul, Fran?oise,Miot-Noirault, Elisabeth,Moreau, Emmanuel,Navarro-Teulon, Isabelle,Quintana, Mercedes,Rondon, Aurélie,Taiariol, Ludivine,Ty, Nancy
supporting information, (2020/07/21)
The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.
